



**NORTHWEST
BIOTHERAPEUTICS**

Northwest
Biotherapeutics, Inc.

7600 Wisconsin Ave
Suite 750
Bethesda, MD 20814

www.nwbio.com

OTCBB: NWBO

Northwest Biotherapeutics To present at Next Generation Vaccine Conference

Highlights Include Clinical Trial Updates

BETHESDA, MD – July 18, 2008 – Northwest Biotherapeutics, Inc. (OTCBB: NWBO.OB; AIM, NWBTS and NWBT), (the “Company or NWBT”), today announced that Dr. Alton L. Boynton, its President and Chief Executive Officer, will deliver a presentation updating the Company’s progress in the development of dendritic vaccines for the treatment of cancer, at the “Next Generation Vaccines” conference. The conference will be held on 17 & 18 July, at the Gaylord National Resort and Convention Center in National Harbor, Maryland, USA. Dr. Boynton is scheduled to present as part of the Advances in Cancer Vaccines session on July 18th @ 11:15 am EST.

Dr. Boynton will provide an update on NWBT’s product candidates, including therapeutic cancer vaccines DCVax[®]-Brain for the treatment of Glioblastoma multiforme and DCVax[®]-Prostate for hormone-independent prostate cancer.

- Ends -

For further information, please contact:

Northwest Biotherapeutics
Anthony P. Deasey, Chief Financial Officer

+1 240-497-9024

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform



**NORTHWEST
BIOTHERAPEUTICS**

Northwest
Biotherapeutics, Inc.

7600 Wisconsin Ave
Suite 750
Bethesda, MD 20814

www.nwbio.com

OTCBB: NWBO

technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company is currently conducting a large Phase II clinical trial in GBM, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has started a Phase I/II trial with DCVax[®] directed to ovarian cancer. The Company's second technology platform, involving antibodies to CXCR4, is at the late pre-clinical development stage.

For further information, please visit the company web site at www.nwbio.com

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in the Phase II trial of DCVax[®]-Brain and complete the trial on a timely basis, risks related to meeting the clinical endpoints in the planned Phase II clinical trial of DCVax[®]-Brain, risks related to manufacturing, risks related to the Company's ability to initiate, and enroll patients in, the planned Phase III trial of DCVax[®]-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVax[®]-Prostate or DCVax[®]-Brain will demonstrate safety and efficacy, and the timely performance of third parties. Additional information on these and other factors, which could affect the Company's results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-



**NORTHWEST
BIOTHERAPEUTICS**

Northwest
Biotherapeutics, Inc.

7600 Wisconsin Ave
Suite 750
Bethesda, MD 20814

www.nwbio.com

OTCBB: NWBO

looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.